Navigation Links
Einstein awarded NIH grant to study drug-resistant TB
Date:6/2/2010

June 2, 2010 (BRONX, NY) The National Institutes of Health (NIH) has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis (XDR-TB) is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

"Most cases of XDR-TB are thought to arise when people infected with susceptible strains of TB don't take their medications correctly or are prescribed the wrong medications," explained principal investigator Sarita Shah, M.D., M.P.H., assistant professor of medicine and of epidemiology & public health. "These medication failures encourage the growth of drug-resistant strains of TB bacteria a phenomenon known as amplified resistance."

XDR-TB can also arise when someone who never had TB, or who had TB that was cured, is directly infected with a drug-resistant strain of TB. "Person-to-person transmission of XDR-TB was believed to be rare," said Dr. Shah. "But increasing evidence suggests that it's much more common than previously thought. We estimate that two-thirds to three-quarters of XDR-TB cases arise this way."

Dr. Shah will prospectively interview and analyze the medical records of 400 patients with XDR-TB to determine how many new cases develop due to person-to-person transmission compared with new cases of amplified resistance. The study will take place in the area of Tugela Ferry in the KwaZulu-Natal district of South Africa which has exceedingly high rates of XDR-TB.

Adding to their woes, many TB patients in Tugela Ferry are co-infected with HIV, the virus that causes AIDS. (South Africa has more people infected with HIV than any other country in the world.) Studies have found that TB patients co-infected with HIV face a higher risk of developing active TB disease than patients free of HIV. Thus, an HIV-infected person who contracts XDR-TB through person-to-person transmission due to prolonged hospital stays for other medical conditions, for example is more likely to develop active XDR-TB than a person without HIV.

Efforts to curb the growing XDR-TB epidemic currently focus primarily on preventing amplified resistance: healthcare workers directly observe patients to ensure they adhere to their medication regimen. But if person-to-person transmission turns out to be the major source of drug-resistant TB, public health agencies will have to adjust their XDR-TB control efforts by emphasizing measures that prevent people from infecting others, including earlier diagnosis and treatment and more rigorous infection control measures. The findings would be applicable throughout sub-Saharan Africa, where the TB epidemic follows patterns similar to those in Tugela Ferry.

To determine how person-to-person XDR-TB transmission is most likely to occur within families, among co-workers, or perhaps among people admitted to the hospital at the same time Dr. Shah will combine classic contact investigation methods with advanced epidemiologic techniques (including molecular genotyping) and social network analysis. Molecular genotyping will allow the researchers to identify clusters of particular strains of XDR-TB.

"Then, using contact investigation and social network analysis, we'll investigate how the people in those clusters are linked," said Dr. Shah, noting that this is the first time such an approach will be used to study TB transmission in a population with a high prevalence of HIV.

"Working in Tugela Ferry ground zero for the emerging XDR-TB epidemic Dr. Shah has been at the forefront of understanding the deadly duet between TB and HIV," said Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology at Einstein and director of the Center for AIDS Research (CFAR), which coordinates the diverse AIDS research efforts at Einstein and Montefiore Medical Center, the University Hospital and Academic Medical Center for Einstein. "This study is critical for learning how co-infection with HIV increases mortality from TB and promotes the emergence of extensively drug-resistant TB strains."

Dr. Shah's initial work on transmission patterns of XDR-TB was funded by the Einstein-Montefiore CFAR. The current study, "Transmission of HIV-Associated XDR-TB in rural South Africa," is funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Her Einstein co-investigators include William R. Jacobs, Jr., Ph.D., Michelle H. Larsen, Ph.D., Neel R. Gandhi, M.D., and Moonseong Heo, Ph.D.


'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert  

Related medicine news :

1. Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists
2. Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60
3. Co-Founder of Baby Einstein Files Open-Records Complaint for Access to University of Washington Research
4. NIH awards $10M to Einstein for diabetes research
5. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
6. Prominent Beverly Hills Law Firm Awarded $16.5 Million Medical Malpractice Jury Verdict
7. pcRUSH.com / Atman, Inc. is Awarded General Services Administration (GSA) Schedule (GS-35F-0099W)
8. $12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP)
9. Jefferson awarded multi-million dollar NIH grant
10. Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres
11. Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Einstein awarded NIH grant to study drug-resistant TB
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... 'Tis the ... disrupt daily routines. That means it's also the season when eating healthy, staying active, ... with diabetes) on schedule is harder to do. , "Shopping trips, parties and ...
(Date:12/6/2016)... Dublin, CA (PRWEB) , ... December 06, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... Health Fundamentals certificate program focused on providing occupational safety and health training to ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham ... announce the arrival of the newest Sciton laser in January 2017. The Halo ... tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All Children’s ... of young athletes. Over the course of three years, researchers will study concussions and ... The mouth guards, equipped with special sensors, will track the location and force of ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 2 clinical study of sotagliflozin, a dual SGLT1 and ... the leading global organization funding type 1 diabetes research. ... trial, which randomized a total of 87 patients, was ... dose of sotagliflozin compared to a placebo control in ...
(Date:12/5/2016)... Mich. , Dec. 5, 2016  Sharn Anesthesia ... preferred anesthesia sales and distribution partner for Salter Labs.  ... of the Year in recognition of outstanding sales performance. ... devices for respiratory and anesthesia care, including the market ... is also the master distributor of the Parker Flex-Tip® ...
(Date:12/5/2016)... TrainerMD , the first HIPAA compliant software collaboration platform for patients, ... . Styku, a California -based software ... world-class, real-time 3D body scanning and analysis. Together with its other ... and feel their health like never before. ... , , ...
Breaking Medicine Technology: